Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Rating ) has been assigned a consensus rating of 'Moderate Buy' from the ten ratings firms that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $12.75. Several analysts recently weighed in on the stock. SpectralCast reiterated a 'maintains' rating on shares of Pacific Biosciences of California in a report on Wednesday, May 3rd.

https://www.dailypolitical.com/2023/06/10/pacific-biosciences-of-california-inc-nasdaqpacb-given-average-rating-of-moderate-buy-by-brokerages.html

#dailypolitical